FCM
CTMX icon

Farallon Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Farallon Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-148,952
Closed -$1.24M – 126
2020
Q2 		$1.24M Buy
+148,952
New +$1.38M 0.01% 118

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Farallon Capital Management's CTMX Position: Q3 2020 in Review

Farallon Capital Management sold out of CytomX Therapeutics (CTMX) in Q3 2020, closing a stake of 148,952 shares — an estimated $1.24M sold.

Farallon Capital Management first reported a position in CTMX in Q2 2020 and held it in 1 quarter. The position peaked at $1.24M in Q2 2020. 130 funds tracked by Wall St. Rank hold CTMX as of Q3 2020.

  • Farallon Capital Management reported no remaining CytomX Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Farallon Capital Management sold 148,952 CytomX Therapeutics shares in Q3 2020, an estimated $1.24M.
  • Farallon Capital Management first reported a position in CytomX Therapeutics in Q2 2020 and held it in 1 quarter.
  • Farallon Capital Management's CytomX Therapeutics position peaked at $1.24M in Q2 2020.
  • 130 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2020.

Based on Farallon Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.